- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01829763
Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb
Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflex with exaggerated tendon jerk (Lance 1980). Patients with brain lesion often display spasticity due to the interruption of the descending pathways that control the spinal reflex networks, which results in hyperexcitability of the monosynaptic reflex triggered by stretch of the muscle spindles. Spasticity in lower limb muscle impairs the gait, especially in strokes that are the main cause of neurological disability. While 80% of the stroke survivors recover the ability to walk, the poor quality of their gait constitutes a serious handicap in daily life (Bensoussan et al. 2004; Bensoussan et al. 2006).
Local injection of Botulinum toxin (BTx) has become a mainstay of the treatment of focal spasticity, particularly in post-stroke patients. BTx weakens the excessive muscle contraction by blocking the release of acethylcholine from motoneuron terminals at the neuromuscular junction and transiently paralyzing the muscle for several months. Besides this peripheral action, BTx is assumed to have also a central effect (Curra et al. 2004; Gracies 2004; Krishnan 2005; Palomar and Mir 2012). In particular, by affecting also the fusimotor synapses on intrafusal muscles fibers (Rosales and Dressler 2010; Trompetto et al. 2008; Trompetto et al. 2006), BTx may reduce the discharge from muscle spindles, which may be indirectly responsible for functional changes in central motor mechanisms at both spinal and supraspinal levels. Animal experiments also suggested that BTx is carried by retrograde axonal transport to motoneuron soma and possibly transynaptically, and can affect the spinal cholinergic synaptic transmission in the spinal cord. Until now, electrophysiological findings are limited and controversial, probably due to the various motor disorders investigated, the physiological mechanisms tested and the different toxin injection protocols used in the few studies available (Frascarelli et al. 2011; Girlanda et al. 1997; Modugno et al. 1998; Naumann and Reiners 1997; Pauri et al. 2000; Priori et al. 1995; Wohlfarth et al. 2001). Hence, the central action of the toxin in spasticity remains uncertain.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: laurent bensoussan
- Email: laurent.bensoussan@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Recruiting
- Assistance Publique Hopitaux de Marseille
-
Contact:
- laurent bensoussan
- Email: laurent.bensoussan@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- More than 18-years-old Patient
- Patient presenting a hemiplegia séquellaire of an AVC above - tentoriel dating more than 12 months
- Patient presenting a spasticité of the muscles of the leg
- Patient for him(it) ( a ) which an indication of treatment(processing) by botulinal toxin is carried(worn)
- Patient not having received from treatment(processing) by botulinal toxin at the level of the lower limb for six months
- Patient not having benefited from alcoholization or surgical gesture(movement) at the level of the lower limb for twelve months
- Spasticité focused the muscles of leg: soleus, gastrocnémiens, with score of Ashworth > or = 2 on the concerned muscles and/or the presence of a clonus on the soleus or gastrocnémiens,
Exclusion Criteria:
- Patient for him(it) ( a ) which the upright posture and/or the walking(step) are impossible
- Patient presenting a contraindication to the use of the botulinal toxin
- Patient presenting a contraindication to the use of the intramuscular way
- Patient susceptible not to participate in the totality of the study
- Woman pregnant or susceptible to be pregnant during the year
- Patient who can not give himself(itself) his consent (held(detained), major under guardianship)
- Patient incapable to understand(include) the nature and the purposes of the study, or presenting difficulties of understanding which can compromise the good progress of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: botox
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
injection Botulinum toxin type-A (BTx-A)
Time Frame: 24 MONTHS
|
24 MONTHS
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-000600-42
- 2013-02 (CCRRC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemiplegic Patients Post-AVC
-
Rennes University HospitalCompleted
-
Yonsei UniversityCompletedChronic Post-stroke Hemiplegic PatientsKorea, Republic of
-
EarlySense Ltd.WithdrawnPost Operative Patient | Patients Requiring PCA | Respiratory Patients | Patients in Risk of FallUnited States
-
University of California, DavisCompleted
-
Transonic Systems Inc.Russian Academy of Medical SciencesCompletedPost Cardiac Surgery PatientsRussian Federation
-
Shiraz University of Medical SciencesCompletedPost Coronary Bypass Surgery PatientsIran, Islamic Republic of
-
Siriraj HospitalUnknownPatient Relations, Nurse | Post-operative PatientsThailand
-
University Hospital, CaenCompleted
-
Beth Israel Deaconess Medical CenterWithdrawnPost-operative Recovery for Cesarean Hysterectomy PatientsUnited States
-
Bispebjerg HospitalCompletedRehabilitation Strategies for Elderly Post-Operative PatientsDenmark
Clinical Trials on injection botox
-
Hospices Civils de LyonCompletedAmyotrophic Lateral Sclerosis | SialorrheaFrance
-
Michael Zell, MDNot yet recruitingOveractive Bladder | Benign Prostatic HyperplasiaUnited States
-
Rebecka OhmRecruitingFacial Palsy | Bell Palsy | Facial Paralysis | Synkinesis | Peripheral Facial Palsy | Peripheral Facial ParalysisSweden
-
Damascus UniversityCompletedNocturnal BruxismSyrian Arab Republic
-
AHMED FARAHAT HASSANUnknown
-
Assiut UniversityUnknown
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedUrinary Incontinence, Stress | Urinary Incontinence, UrgeUnited States
-
Beni-Suef UniversityCompletedBenign Prostatic HyperplasiaEgypt
-
University of AlbertaWithdrawnHemorrhagic Stroke | Reversible Cerebral Vasoconstriction Syndrome | Cerebral Venous Sinus Thrombosis | Headache, Migraine | Stroke (CVA) or TIA | Botulinum Toxins, Type A | Carotid Dissection Artery | Vertebral Dissection ArteryCanada
-
Zagazig UniversityCompletedChronic Anal FissureEgypt